EDWARDS LIFESCIENCES
-
Edwards Lifesciences beats profit estimate on strength in heart devices
Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, especially from older adults.
-
Becton Dickinson looks to divest life sciences unit at $30 billion valuation, source says
-
Edwards forecast fourth-quarter sales below expectations on soft demand for heart devices
-
Hurricane-related IV fluid shortage could hurt medical device makers
-
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln
-
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
